Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.

Abstract

Ipilimumab, a fully human monoclonal antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), is the new hope in the treatment of patients with advanced melanoma. Anti-CTLA-4 antibodies enhance T cell responses in vitro and in vivo and activate proliferation of tumour-specific T cells. The blockade of CTLA-4 by ipilimumab leads to immune… (More)

Topics

  • Presentations referencing similar topics